Objective
Currently, the in vivo step in the drug discovery process is always performed using the mouse model. This step is expensive and time-consuming, with an average cost of 40k€ per molecule tested and an average duration of 6-9 months. It represents a huge obstacle for the pharmaceutical industry, leading to fewer new drugs brought to market each year, and insufficient treatments for severe pathologies such as cancer or orphan diseases. INOVOTION can play a major role in solving this huge societal issue: we have the technology to revolutionize drug discovery by automating in vivo drug evaluation for efficacy and toxicity.
INOVOTION is a spin-off of the University of Grenoble, founded in 2014 by Prof. Viallet. Our researchers have been working since 2009 on a new proprietary technology to perform “in ovo” assays that precede mouse testing, using chick embryos. Our tests allow researchers to eliminate low-value molecules at an early stage in the process, and to dedicate mouse testing for high-potential molecules only. Furthermore, our technology is reliable, reproducible, highly sensitive, fast and automatable.
The successful 150 studies we performed for big pharma, small biotechs and academics (in the USA, France, UK, Japan, South Africa, Czech Republic and the United Arab Emirates) have confirmed the market demand for our technology.
The worldwide market for in vivo testing is about 30 billion euros per year, mainly for cancer research, and INOVOTION has the technology to meet the market's needs. For each 1% in market share we cover, we could save the pharmaceutical industry up to 240 M€.
The OVOMATIC project aims to initiate an automated “in ovo” process including developing a robot tool head prototype, and finalise the commercial and financial strategies of our approach. The long-range impact of the OVOMATIC project is to introduce this new tool into the pharmaceutical landscape, greatly increasing the productivity of our clients' anti-cancer drug discovery efforts.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine pharmacology and pharmacy drug discovery
- social sciences economics and business economics production economics productivity
- medical and health sciences clinical medicine oncology
- medical and health sciences basic medicine pathology
- medical and health sciences clinical medicine embryology
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.1.4. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-1 - SME instrument phase 1
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-SMEInst-2016-2017
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
38700 LA TRONCHE
France
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.